Multiple Myeloma: E1A11 (Iowa Cancer Specialists)

ECOG-ACRIN E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Objective

This study has two parts, the first part is related to the initial treatment of patients with multiple myeloma (also called induction) and a second part is related to continued long term control of the myeloma (also called maintenance).

The purpose of the first part of the study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone, on patients with multiple myeloma to find out which is better. In this study, patients will get either the combination that contains carfilzomib or that containing bortezomib. They will not get both.

Following the initial treatment of multiple myeloma (induction), the second part of the study will examine if it is better to continue lenalidomide until the myeloma comes back or limit it for a defined period of 2 years.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Multiple Myeloma
Sponsor(s)
Eastern Cooperative Oncology Group
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email